CompletedPhase 2NCT03929666
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Studying Carcinoma of gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jazz Pharmaceuticals
- Principal Investigator
- Phillip Garfin, MD, PhD, M.D., Ph.DJazz Pharmaceuticals
- Intervention
- ZW25 (Zanidatamab)(drug)
- Enrollment
- 74 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (23)
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- The Cancer and Hematology Centers, Grand Rapids, Michigan, United States
- Nebraska Methodist Hospital, Omaha, Nebraska, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Virginia Mason Medical Center, Seattle, Washington, United States
- The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
- Centro de Investigacion Clinica SAGA, Santiago, Chile
- Icegclinic Research & Care, Santiago, Chile
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03929666 on ClinicalTrials.govOther trials for Carcinoma of gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06901622Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaThe First Affiliated Hospital of Zhengzhou University
- RECRUITINGNCT07337850Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersTata Memorial Centre
- RECRUITINGPHASE2NCT06440993Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- ACTIVE NOT RECRUITINGPHASE2NCT05712356A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsLisata Therapeutics, Inc.
- ENROLLING BY INVITATIONPHASE3NCT06671418Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary ObstructionErasmus Medical Center
- RECRUITINGNCT05404347NGS in Gallbladder Cancer and Response to TreatmentBanaras Hindu University
See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →